EPAS1 and clear cell renal carcinoma: To determine whether the effect of EGLN1 on antiviral immune responses is dependent of VHL1, we used two clear cell renal cell carcinoma cell lines, RCC4 (VHL-deficient; with both intact HIF1α and intact HIF2α) and 786-O (VHL-deficient; with intact HIF2α but deficient HIF1α)57,58.